Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.63Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -5.84%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals demonstrated significant financial growth and strong pipeline advancements, with notable achievements including the approval of CTEXLI and the expansion of LIVMARLI's market. However, high operating expenses and challenges in fully penetrating the Alagille syndrome market were noted. The positive aspects of financial performance and pipeline progress outweigh the challenges, indicating a strong outlook for the company.Company Guidance
During the Mirum Pharmaceuticals fourth quarter and year-end 2024 conference call, the company provided significant guidance for the upcoming year. The 2024 total net product sales reached $336.4 million, surpassing the upper-end of their revised guidance range, with LIVMARLI contributing $213 million. The company expects to increase this by nearly $100 million in 2025, forecasting net product sales between $420 million and $435 million. Mirum plans to expand the global presence of LIVMARLI, particularly in Alagille syndrome and PFIC, and capitalize on the recent approval of CTEXLI for CTX in the US. They also aim to push Volixibat towards pivotal data in adult cholestasis and initiate a Phase 2 study for MRM-3379 in Fragile X syndrome. The company reported ending 2024 with cash and investments totaling $293 million, highlighting a positive cash flow trajectory expected to continue in 2025.Strong Financial Performance
Mirum Pharmaceuticals reported total net product sales of $336.4 million for 2024, exceeding the upper-end of their revised guidance range. This represents a significant increase from $178.9 million in 2023.
LIVMARLI Sales Growth
LIVMARLI achieved total net product sales of $213.3 million in 2024, representing a 50% increase compared to 2023. The growth was driven by increased demand in Alagille syndrome and PFIC.
New Product Approval
The FDA approved CTEXLI for cerebrotendinous xanthomatosis (CTX) in adults, providing a new treatment option with seven years of exclusivity.
Pipeline Advancements
Positive interim results for Volixibat in VISTAS PSC and VANTAGE PBC studies led to breakthrough designation in PBC. Additionally, the Phase 3 EXPAND study of LIVMARLI in cholestatic pruritus was initiated.
Strong Cash Position
Mirum ended 2024 with $293 million in cash, cash equivalents, and investments, and the company was cash flow positive for the year.
---
MIRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MIRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $50.52 | $46.98 | -7.01% |
| Nov 12, 2024 | $41.61 | $42.28 | +1.61% |
| Aug 07, 2024 | $38.96 | $39.87 | +2.34% |
| May 08, 2024 | $25.04 | $25.83 | +3.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mirum Pharmaceuticals Inc (MIRM) report earnings?
Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Mirum Pharmaceuticals Inc (MIRM) earnings time?
Mirum Pharmaceuticals Inc (MIRM) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIRM EPS forecast?
MIRM EPS forecast for the fiscal quarter 2024 (Q4) is -0.26.
---